GPT and metabolic dysfunction-associated steatotic liver disease: In a study involving 19 patients with T2D and NAFLD, researchers found that, after 6 months of treatment with the combination of simvastatin (statins) and ezetimibe (a cholesterol absorption inhibitor), significant reductions were observed in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), low-density lipoprotein (LDL), and other markers, which suggested that this combination therapy is an effective treatment approach for patients with T2D and NAFLD (176).